How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,360 results for

Digoxin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Increased All-Cause Mortality Associated With Digoxin Therapy in Patients With Atrial Fibrillation: An Updated Meta-Analysis. (PubMed)

Increased All-Cause Mortality Associated With Digoxin Therapy in Patients With Atrial Fibrillation: An Updated Meta-Analysis. Digoxin is still commonly used in atrial fibrillation (AF) patients with and without heart failure (HF) for heart rate control. Studies concerning the detrimental effects of digoxin therapy in AF patients are inconsistent. This updated meta-analysis examined the association of digoxin therapy with all-cause mortality in AF patients, stratified by heart function status (...) . We included observational studies with multivariate-adjusted data on digoxin and all-cause mortality in the analysis. The relative risks (RRs) of all-cause mortality were calculated and reported with 95% confidence intervals (95% CIs). Seventeen studies comprising 408,660 patients were included. Overall, in AF patients, digoxin treatment was associated with a significant increase in all-cause mortality after multivariate-adjustment (RR = 1.22; 95% CI 1.15-1.30). When stratified by heart function

Full Text available with Trip Pro

2015 Medicine

142. Digoxin use after diagnosis of colorectal cancer and survival: A population-based cohort study. (PubMed)

Digoxin use after diagnosis of colorectal cancer and survival: A population-based cohort study. Digoxin has been shown to affect a number of pathways that are of relevance to cancer, and its use has been associated with increased risks of breast and uterus cancer and, more recently, a 40% increase in colorectal cancer risk. These findings raise questions about the safety of digoxin use in colorectal cancer patients, and, therefore, we investigated whether digoxin use after colorectal cancer (...) diagnosis increased the risk of colorectal cancer-specific mortality.A cohort of 10,357 colorectal cancer patients newly diagnosed from 1998 to 2009 was identified from English cancer registries and linked to the UK Clinical Practice Research Datalink (to provide digoxin and other prescription records) and to the Office of National Statistics mortality data (to identify 2,724 colorectal cancer-specific deaths). Using time-dependent Cox regression models, unadjusted and adjusted HRs and 95% confidence

Full Text available with Trip Pro

2015 Cancer Epidemiology & Biomarkers and Prevention

143. Digoxin Is Associated With Increased All-cause Mortality in Patients With Atrial Fibrillation Regardless of Concomitant Heart Failure: A Meta-analysis. (PubMed)

Digoxin Is Associated With Increased All-cause Mortality in Patients With Atrial Fibrillation Regardless of Concomitant Heart Failure: A Meta-analysis. For decades, digoxin has been widely used to control ventricular rate in atrial fibrillation (AF). However, it remains controversial as to whether digoxin is associated with increased mortality in AF. In this study, we searched relevant studies that were published before December 1, 2014, in PubMed, EMBASE, and the Cochrane central databases. We (...) systematically reviewed the references and performed a meta-analysis of 8 carefully selected studies with 302,738 patients who were included for the final analysis. It was shown that digoxin use was associated with increased risk of all-cause mortality in AF overall [hazard ratio (HR) = 1.375, 95% confidence intervals (CI), 1.201-1.574, P = 0.0001]. Subgroup analysis further revealed that digoxin was associated with increased all-cause mortality in patients with AF, which was complicated by heart failure (HF

2015 Journal of cardiovascular pharmacology

144. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. (PubMed)

Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. 26374771 2016 04 28 2018 10 23 1756-1833 351 2015 Sep 15 BMJ (Clinical research ed.) BMJ Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. h4937 10.1136/bmj.h4937 eng Published Erratum 2015 09 15 England BMJ 8900488 0959-8138 BMJ. 2015;351:h4451 26321114 2015 9 17 6 0 2015 9 17 6 0 2015 9 17 6 1 epublish 26374771 10.1136

Full Text available with Trip Pro

2015 BMJ (Clinical research ed.)

145. An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Heal

An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Heal An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine (...) , and Dextromethorphan in Healthy Subjects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin

2015 Clinical Trials

146. Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects

Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02472236 Recruitment Status : Completed First Posted : June 15, 2015 Last Update Posted : January 24, 2017

2015 Clinical Trials

147. The Pharmacokinetic Study of the Combination of Digoxin and Polythylene Glycol Loxenatide Injection in Healthy Subjects

The Pharmacokinetic Study of the Combination of Digoxin and Polythylene Glycol Loxenatide Injection in Healthy Subjects The Pharmacokinetic Study of the Combination of Digoxin and Polythylene Glycol Loxenatide Injection in Healthy Subjects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. The Pharmacokinetic Study of the Combination of Digoxin and Polythylene Glycol Loxenatide Injection in Healthy Subjects The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02451527 Recruitment Status : Completed First

2015 Clinical Trials

148. A Prospective Study of Different Digoxin Treatment Regimens in Egyptian Hospital

A Prospective Study of Different Digoxin Treatment Regimens in Egyptian Hospital A Prospective Study of Different Digoxin Treatment Regimens in Egyptian Hospital - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. A Prospective Study of Different Digoxin Treatment Regimens in Egyptian Hospital The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02489786 Recruitment Status : Completed First Posted : July 3, 2015 Last Update Posted : July 7, 2015 Sponsor: Cairo University Information provided by (Responsible

2015 Clinical Trials

149. Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. (PubMed)

Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. To review digoxin use in systolic congestive heart failure, atrial fibrillation, and after myocardial infarction.A comprehensive PubMed search was performed using the key words "digoxin and congestive heart failure", "digoxin and atrial fibrillation", "digoxin, atrial fibrillation and systolic congestive heart failure", and "digoxin and myocardial infarction". Only articles written (...) in English were included in this study. We retained studies originating from randomized controlled trials, registries and included at least 500 patients. The studies included patients with atrial fibrillation or heart failure or myocardial infarction and had a significant proportion of patients (at least 5%) on digoxin. A table reviewing the different hazard ratios was developed based on the articles selected. Our primary endpoint was the overall mortality in the patients on digoxin vs those without

Full Text available with Trip Pro

2015 World journal of cardiology

150. Digoxin may not improve prognosis in AF

Digoxin may not improve prognosis in AF Digoxin may not improve prognosis in AF – All About Cardiovascular System and Disorders Now Trending: | November 1, 2015 | | A recent study published in Circulation [1] evaluated the use of various rate control modalities in atrial fibrillation. They evaluated the risk of mortality in a population based study of about 270 thousand patients. In this study, about 44 thousand received beta blockers while over 18 thousand received calcium channel blockers (...) and about 39 thousand received digoxin. No rate reducing agents were received by about 169 thousand patients, which incidentally constituted the majority of this study population. Use of beta blockers and calcium channel blockers were found to confer a lower risk of mortality compared to no treatment while use of digoxin was associated with a poor prognosis. Authors while calling for a prospective study endorsed the current guideline recommendation to use beta blockers and calcium channel blockers

2015 Cardiophile MD blog

151. The effect of maternal obesity on the expression and functionality of placental P-glycoprotein: Implications in the individualized transplacental digoxin treatment for fetal heart failure. (PubMed)

The effect of maternal obesity on the expression and functionality of placental P-glycoprotein: Implications in the individualized transplacental digoxin treatment for fetal heart failure. Placental P-glycoprotein (P-gp) plays a significant role in controlling digoxin transplacental rate. Investigations on P-gp regulation in placenta of women with different pregnant pathology are of great significance to the individualized transplacental digoxin treatment for fetal heart failure (FHF (...) /TNF-α protein expression were determined by real-time quantitative PCR and western-blot, respectively. Maternal plasma and fetal-unit digoxin concentrations were detected by a commercial kit assay.Both ABCB1 gene mRNA and protein expression of obesity group was significantly lower than that of control group in human. The high-fat dietary intervention resulted in an overweight phenotype, a significant increased Lee's index, higher levels of plasma glucose, HDL-C, LDL-C, insulin and TGs, increased

2015 Placenta

152. Digoxin and mortality: lessons for observational studies (PubMed)

Digoxin and mortality: lessons for observational studies 26390833 2016 04 20 2018 12 02 1365-2125 81 1 2016 Jan British journal of clinical pharmacology Br J Clin Pharmacol Digoxin and mortality: lessons for observational studies. 4-5 10.1111/bcp.12791 de Boer Anthonius A Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands. a.deboer@uu.nl. Cohen Adam F AF Centre for Human Drug Research, Leiden, the Netherlands. eng Editorial Comment 2015 11 20 England Br (...) J Clin Pharmacol 7503323 0306-5251 0 Cardiotonic Agents 73K4184T59 Digoxin IM BMJ. 2015;351:h4451 26321114 Atrial Fibrillation drug therapy Cardiotonic Agents therapeutic use Digoxin therapeutic use Heart Failure drug therapy Humans 2015 09 19 2015 09 21 2015 9 23 6 0 2015 9 24 6 0 2016 4 21 6 0 ppublish 26390833 10.1111/bcp.12791 PMC4693562 BMJ. 2015;351:h4451 26321114 Clin Pharmacol Ther. 1997 Mar;61(3):275-91 9084453 Stat Med. 2009 Nov 30;28(27):3437-53 19708037 Eur J Epidemiol. 2010 Apr;25(4

Full Text available with Trip Pro

2015 British journal of clinical pharmacology

153. Junctional Bradycardia as Early Sign of Digoxin Toxicity in a Premature Infant with Congestive Heart Failure due to a Left to Right Shunt (PubMed)

Junctional Bradycardia as Early Sign of Digoxin Toxicity in a Premature Infant with Congestive Heart Failure due to a Left to Right Shunt Introduction Congestive heart failure due to left to right cardiac shunt is usually managed medically with diuretics, angiotensin converting enzyme inhibitors, and, in some cases, with the addition of digoxin. Case We report a 31-week gestation premature male infant who did not respond to such treatment and developed hyperaldosteronism and severe hypokalemia (...) secondary to activation of the renin angiotensin aldosterone system. The hypokalemia was not responsive to intravenous KCL supplementation and induced digoxin toxicity despite a relatively normal digoxin level. The earliest signs of digoxin toxicity in the patient were junctional rhythm and bradycardia. The discontinuation of digoxin and the administration of digoxin specific immunoglobulin fragments (Fab) reversed those changes. The addition of spironolactone (an aldosterone antagonist) had a dramatic

Full Text available with Trip Pro

2015 AJP Reports

154. Digoxin Use to Control Ventricular Rate in Patients with Atrial Fibrillation and Heart Failure Is Not Associated with Increased Mortality (PubMed)

Digoxin Use to Control Ventricular Rate in Patients with Atrial Fibrillation and Heart Failure Is Not Associated with Increased Mortality Introduction. Digoxin is used to control ventricular rate in atrial fibrillation (AF). There is conflicting evidence regarding safety of digoxin. We aimed to evaluate the risk of mortality with digoxin use in patients with AF using meta-analyses. Methods. PubMed was searched for studies comparing outcomes of patients with AF taking digoxin versus no digoxin (...) , irrespective of heart failure status, digoxin is associated with increased all-cause mortality (HR [1.23], 95% confidence interval [CI] 1.16-1.31). However, digoxin is not associated with increased mortality in patients with AF and HF (HR [1.08], 95% CI 0.99-1.18). In AF patients without HF digoxin is associated with increased all-cause mortality (HR [1.38], 95% CI 1.12-1.71). Conclusion. In patients with AF and HF, digoxin use is not associated with an increased risk of all-cause mortality when used

Full Text available with Trip Pro

2015 Cardiology research and practice

155. Transport of digoxin-loaded polymeric nanoparticles across BeWo cells, an in vitro model of human placental trophoblast (PubMed)

Transport of digoxin-loaded polymeric nanoparticles across BeWo cells, an in vitro model of human placental trophoblast Fetal arrhythmias can lead to fetal congestive heart failure and hydrops fetalis. Digoxin (the first-line treatment) has low transplacental permeability and high risk of maternal side effects. Biodegradable digoxin-loaded PEGylated poly(lactic-co-glycolic acid) nanoparticles may increase digoxin transport across BeWo b30 cell monolayers (an in vitro model of trophoblast (...) in human placenta) by reducing the drug's interaction with P-gp. Results/methodology: The nanoparticles showed high encapsulation efficiency and sustained release over 48 h. Transport studies revealed significantly increased permeability across BeWo cell layers of digoxin-loaded nanoparticles when compared with free digoxin. P-gp inhibition also increased the permeability of digoxin, but not digoxin-loaded nanoparticles.This represents a novel treatment strategy for fetal cardiovascular disease which

Full Text available with Trip Pro

2015 Therapeutic delivery

156. ABCB1 gene variants, digoxin and risk of sudden cardiac death in a general population. (PubMed)

ABCB1 gene variants, digoxin and risk of sudden cardiac death in a general population. The ATP-binding cassette B1 (ABCB1) gene encodes P-glycoprotein, a transport protein, which plays an important role in the bioavailability of digoxin. We aimed to investigate the interaction between variants within the ABCB1 gene and digoxin on the risk of sudden cardiac death (SCD).Within the Rotterdam Study, a population-based cohort study in persons 45 years of age and older, we used Cox regression (...) to analyse the association between three polymorphisms that have been associated with digoxin bioavailability, extracted from 1000-Genomes imputed ABCB1 genotypes and the risk of SCD, stratified by digoxin use.In a total study population of 10,932 persons, 419 SCDs occurred during a median follow-up of 9.8 years. In non-users of digoxin, the risk of SCD was not different across genotypes. In digoxin users, homozygous T allele carriers of C1236T (HR 1.90; 95% CI 1.09 to 3.30; allele frequency 0.43

2015 Heart

157. Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. (PubMed)

Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. Digoxin is widely used for rate control of atrial fibrillation. However, recent studies have reported conflicting results on the association of digoxin with mortality when used in patients with atrial fibrillation. Moreover, the relationship of digoxin use to mortality in hypertensive patients with atrial fibrillation has not been examined.All-cause mortality was examined in relation to in-treatment digoxin use (...) in 937 hypertensive patients with ECG left ventricular hypertrophy in atrial fibrillation at baseline (n = 134) or who developed atrial fibrillation during follow-up (n = 803), randomly assigned to losartan or atenolol-based treatment, in post-hoc analysis of a substudy of the Losartan Intervention For Endpoint Reduction in hypertension (LIFE) trial. During 4.7 ± 1.1 years of mean follow-up, 167 patients died (17.8%) and 372 (39.7%) were treated with digoxin. In univariate Cox analyses, in-treatment

2015 Journal of Hypertension

158. A Phase 1, Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of TAK-272 and the Effect of TAK-272 on the Pharmacokinetics of Digoxin and Midazolam

A Phase 1, Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of TAK-272 and the Effect of TAK-272 on the Pharmacokinetics of Digoxin and Midazolam Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazolam - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning (...) You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazolam The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02370615 Recruitment Status : Completed First Posted

2015 Clinical Trials

159. Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin

Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect of BI 1181181 (...) on Midazolam, Warfarin, Omeprazole and Digoxin The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02345304 Recruitment Status : Withdrawn First Posted : January 26, 2015 Last Update Posted : March 10, 2015 Sponsor: Boehringer Ingelheim Information provided by (Responsible Party): Boehringer Ingelheim Study

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>